Decreased secretoglobin family 2A member 1expression is associated with poor outcomes in endometrial cancer

Abstract

Endometrial cancer is the most common malignancies in developed countries. The present study aimed to identify the role of secretoglobin family 2A member 1 (SCGB2A1) expression in uteri corpus endometrial carcinoma (UCEC) from The Cancer Genome Atlas (TCGA) database, and determine the SCGB2A1-associated downstream signaling pathways. The clinicopathological characteristics and gene expression data were downloaded from TCGA database. The Kaplan-Meier method and Cox multivariate model were used for survival analysis. Logistic regression was used to analyze the association between the clinicopathological features and SCGB2A1 expression. For validation, data of SCGB2A1 mRNA expression and protein expression were obtained and then survival analysis was performed for 47 patients with endometrial cancer from the Fudan University Shanghai Cancer Center (FUSCC). In TCGA dataset, SCGB2A1 expression was significantly higher in tumor tissues (n=528) compared with normal tissues (n=23, P<0.001). The decrease in SCGB2A1 expression in UCEC was significantly associated with age at diagnosis, high tumor grade, residual tumor, positive peritoneal cytology, pelvic lymph node metastasis, para-aortic lymph node metastasis and advanced clinical stage with P<0.05. In the multivariate analysis, SCGB2A1 expression was identified as an independent prognostic factor. In the FUSCC validation set, low SCGB2A1 expression was also associated with worse survival compared with high expression in endometrial cancer (P<0.001). Gene Set Enrichment Analysis revealed that SCGB2A1 may be involved in tumor proliferation and cell cycle regulation. In conclusion, SCGB2A1 may have an important role in the prognosis of UCEC, and has value as a new target for novel therapeutic strategies.

Drug repositioning for immunotherapy in breast cancer using single-cell and spatial transcriptomics analysis

“…We showed the overexpression of ten immunomodulatory peptides in gene level of BC epithelial cells versus normal and validated these results in chromatin level. The elevated expression of these AMPs in BC is also reported previously (30, 34, 35, 39, 40, 43, 44, 57, 58). However, the therapetuic use of these peptide against BC by manipulationg their expression is yet to be explored.…”

Development of a seven-gene tumor immune microenvironment prognostic signature for high-risk grade III endometrial cancer

“…Further, the decreased expression of SCGB2A1 was associated with a poor prognosis. 34 , 35 EMX2 levels in the postmenopausal endometrium were higher than in premenopausal endometrium. 36 Furthermore, EMX2 is significantly downregulated in endometrial cancer.…”

A protein interaction landscape of breast cancer

“…Another PIK3CA interactor, SCGB2A1, is a small secreted protein highly differentially expressed in multiple types of cancer, including breast and endometrium ( 116 , 117 ). Previous studies have shown that SCGB2A1 is expressed at lower levels in luminal BC compared with histologically normal breast epithelium ( 118 ) and that decreased SCGB2A1 expression in endometrial tumors is significantly correlated with higher grade lymph node metastasis, advanced stage cancer, and worse overall survival ( 119 ). Neither the BPIFA1 nor the SCGB2A1 gene harbors recurrent focal deep deletions, missense mutations, or truncating mutations in their coding regions among 996 breast tumors in TCGA analysis ( 2 ).…”